SCHEMBL5669028

SCHEMBL5669028

CCCN(CCC)c1cc2c(cc1CN(Cc1cccc(C#N)c1)C(=O)O)CCC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 9/20 0.39
MEP1A Q16819 1/20 0.38
MEP1B Q16820 1/20 0.38
NR3C1 P04150 1/20 0.38
NLRP3 Q96P20 1/20 0.37
KCNN4 O15554 1/20 0.36
KCNA5 P22460 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
RORC P51449 1/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
KMT2A Q03164 1/20 0.36
DCUN1D1 Q96GG9 1/20 0.35
FFAR1 O14842 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34
FOLH1 Q04609 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1899466 0.90 NLRP3 (0.41) PTGESMEP1AMEP1BNR3C1NLRP3
SCHEMBL5670345 0.88 PKM (0.40) MEN1KMT2A
SCHEMBL16279837 0.86 PTGES (0.38) PTGESNR3C1SLC6A2SLC6A4SLC6A3
SCHEMBL5670858 0.85 LIMK1 (0.40) PTGESNR3C1RORC
SCHEMBL5670550 0.83 NR3C1 (0.43) NR3C1FOLH1
SCHEMBL5671037 0.83 LMNA (0.46) PTGESNR3C1SLC6A2SLC6A4SLC6A3
SCHEMBL5151018 0.82 SLC6A2 (0.39) PTGESMEP1AMEP1BNR3C1NLRP3
SCHEMBL5669275 0.82 CYP2D6 (0.46) SLC6A2SLC6A4SLC6A3MEN1KMT2A
SCHEMBL5669271 0.82 CYP2D6 (0.46) SLC6A2SLC6A4SLC6A3MEN1KMT2A
SCHEMBL5672380 0.81 MAOA (0.38) NR3C1NLRP3KCNN4KCNA5SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1670446-A2 METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION JAPAN TOBACCO INC. (JP) 2006-06-21 EP claimed
WO-2005030185-A2 METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION JAPAN TOBACCO INC. (JP) 2005-04-07 WO claimed
US-20140364493-A1 METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION JAPAN TOBACCO INC. (JP) 2014-12-11 US disclosed
EP-1670446-A2 METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION JAPAN TOBACCO INC. (JP) 2006-06-21 EP disclosed
WO-2005030185-A2 METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION JAPAN TOBACCO INC. (JP) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140364493-A1 METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION CETP, PCSK9, LIPA PTGES 1900/4885MEP1A 1807/4885MEP1B 639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.